ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,377Medicare Part D Prescriptions Filled, Including Refills

Rank: 79 out of 1269

$524K Total Retail Price of All Prescriptions

Rank: 138 out of 1269

374 Patients Receiving at Least One Drug in Part D
92%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

12% of this provider’s 374 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

12% of this provider’s 374 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

0% of this provider’s 8,731 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LEVOTHYROXINE SODIUM 376 358 1 4
FUROSEMIDE 351 340 2 5
METOPROLOL TARTRATE 346 305 3 6
LISINOPRIL 286 254 4 1
ATORVASTATIN CALCIUM 262 245 5 7
AMLODIPINE BESYLATE 245 235 6 2
METFORMIN HCL 223 196 7 9
PRAVASTATIN SODIUM 215 198 8 11
CITALOPRAM HBR 208 199 9 21
OMEPRAZOLE 181 138 10 8
MIRTAZAPINE 175 173 11 24
METOPROLOL SUCCINATE 161 160 12 13
DONEPEZIL HCL 158 158 13 22
SIMVASTATIN 151 138 14 3
RANITIDINE HCL 145 139 15 27
GABAPENTIN 143 136 16 17
WARFARIN SODIUM 134 134 17 12
CLOPIDOGREL 132 126 18 32
HYDROCODONE-ACETAMINOPHEN 117 116 S3 19 20
TRAMADOL HCL 107 107 20 16
TRAZODONE HCL 107 106 20 36
PANTOPRAZOLE SODIUM 100 86 22 18
FAMOTIDINE 91 91 23 85
SERTRALINE HCL 90 90 24 23
PLAVIX 85 85 25 47
OXYCODONE-ACETAMINOPHEN 81 79 S2 26 44
CARVEDILOL 80 80 27 29
NAMENDA 77 77 28 38
TAMSULOSIN HCL 74 74 29 31
ATENOLOL 73 72 30 14
POTASSIUM CHLORIDE 73 69 30 26
LEVEMIR FLEXPEN 72 72 32 195
PAROXETINE HCL 71 71 33 71
GLIPIZIDE ER 70 64 34 102
NYSTOP 68 61 35 186
OXYCONTIN 61 61 S2 36 116
ADVAIR DISKUS 58 48 37 46
HYDROCHLOROTHIAZIDE 56 47 38 10
ALENDRONATE SODIUM 55 41 39 28
CRESTOR 55 42 39 25
LYRICA 54 53 41 92
DIGOXIN 53 53 42 62
DIOVAN 53 49 42 35
LIPITOR 52 45 44 91
CIPROFLOXACIN HCL 52 52 44 66
MUPIROCIN 51 49 46 232
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 10, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.